KW-2401

KW-2401 is an investigational small molecule being developed by Kyowa Kirin. It is a selective antagonist of the adenosine A2A receptor. Adenosine A2A receptors are G protein-coupled receptors that play a significant role in the modulation of neurotransmission in the basal ganglia, particularly in the indirect pathway. By blocking these receptors, KW-2401 aims to improve motor function and reduce the 'off' time associated with levodopa treatment in patients with Parkinson's disease. The drug is designed to provide a non-dopaminergic approach to managing motor fluctuations, potentially offering a therapeutic alternative or adjunct to standard dopamine-replacement therapies.